No Data
Barclays Initiates Guardant Health(GH.US) With Buy Rating, Announces Target Price $60
Guardant Health Initiated With an Overweight at Barclays
Guardant Health's Strategic Growth: Strong Buy Rating Amid Advancements in Reveal MRD Assay
Why Guardant Health, Inc. (GH) Soared At The Start Of The Trading Week
Guardant Health Analyst Ratings
Guardant Health (GH) Receives a Buy From Craig-Hallum